Clinical use of STAT5-activating cytokines and growth factors (e.g. IL-2, erythropoetin) is now commonplace and the recent approval of Jak3 inhibitors for the treatment of autoimmune disease and malignancy points to sustained interest in this pathway (Villarino et al., 2015). This evidence concerns the gene STAT5A and autoimmune disease.